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Background: Postpartum haemorrhage (PPH) accounts for more than 75% of 
maternal deaths from obstetric haemorrhage. In South Africa, maternal mortality 
resulting from postpartum haemorrhage has persistently been shown to be higher in 
HIV positive compared to HIV negative women. It is unknown whether the incidence 
of PPH is higher in HIV positive women; and/or whether HIV positive women have 
more severe bleeding and suffer greater morbidity as a result of PPH.  
 
Aim. The aim of the study was to investigate the effect of HIV infection on the 
incidence and severity of PPH. 
 
Methods: All women delivering at Mowbray Maternity and Groote Schuur Hospital 
in 2009 who had PPH were identified through a manual search of labour ward and 
operating theatre records. The women were categorized according to their HIV status 
as HIV positive, negative and untested. Data was also obtained on HIV status of the 
whole delivery population at these two hospitals. For women with PPH, data 
regarding background characteristics:- blood loss; cause of PPH and management 
provided; severity of and morbidity from PPH was analysed by comparing the HIV 
positive with the HIV negative group. Severity was assessed in terms of blood loss 
alone. Morbidity on the other hand was a composite assessment of blood loss, need 
for blood products, interventions required and complications of the PPH. Data was 
also collected on CD4 counts and treatment provided although the study was not 












Results: During the period under study, Mowbray Maternity Hospital and Groote 
Schuur Hospital registered a total of 15384 deliveries in 2009. 2738 (17.8%) of these 
deliveries were HIV positive, 12151 (79.0%) HIV negative and 495 (3.2%) HIV 
untested.  
A total of 1230 (8.0%) women had recorded blood loss of 500ml or more at the time 
of delivery and fulfilled the criteria for PPH. 270 of these women (22%) were HIV 
positive, 915 (74.4%)  were HIV negative and 45 (3.6%) were HIV untested.  The rate 
of PPH in the HIV positive group was 9.9% compared to 7.5% in the HIV negative 
group and this difference was significant (p<0.001). Uterine trauma at caesarean 
section was the most common cause of PPH in the two groups of patients. It was the 
cause for 92% of PPH cases in HIV positive and 88% in HIV negative women. 
Uterine atony accounted for up to 30% of PPH in the HIV positive group and 29% in 
the HIV negative. Other important causes of PPH included retained placenta and 
products of conception, abruptio placentae and uterine rupture. HIV infection, 
regardless of severity as determined by the level of CD4 count, did not affect the 
severity of PPH. However, more HIV positive women suffered morbidity (p=0.008) 
from PPH despite the similar mean blood loss between the two groups of women 
(p=0.697). Maternal age and obesity did not appear to influence the incidence of PPH 
in HIV positive women. The mode of treatment of HIV also did not influence the 
severity of and the morbidity from PPH. 
 
Conclusion: The results of the study show that postpartum haemorrhage was more 
common and was associated with increased morbidity in HIV positive compared to 
HIV negative women. However, due to the limitations in the study design and the 











risk factor for postpartum haemorrhage. Future research needs to explore the impact 














Postpartum haemorrhage (PPH) remains a major direct cause of maternal mortality 
worldwide. It accounts for 25% of maternal deaths world wide. This is the prevailing 
trend especially in poorly resourced settings such as in sub-Saharan Africa
1
. In South 
Africa, obstetric haemorrhage is the third most common cause of maternal death. It 
accounts for 12.4% of the total number of maternal deaths with PPH making up more 




Despite measures to prevent death from postpartum haemorrhage, the Saving Mothers 
reports between the trienniums 2002 – 2004 and 2005 – 2007 have shown no decrease 
in the trend of deaths due to PPH. The maternal mortality ratio (MMR) due to PPH 
has remained constant at14.7 per 100,000 livebirths during this time.  Of particular 
interest and equally troubling is the finding of an increased number of maternal deaths 
due to PPH in HIV positive compared to HIV negative women. The MMR from PPH 
was 13.8 deaths per 100,000 livebirths in HIV positive women compared to 5.7 per 
100,000 livebirths in HIV negative women.  MMR from PPH was highest in HIV 




According to the confidential enquiry into maternal deaths in the United Kingdom for 
the triennium 2003 – 2005, PPH was also the third commonest cause of maternal 
mortality responsible for 6.6 deaths per million maternities. This rate as in South 













The World Health Report of 2005 notes that the progress in Maternal and Child 
Health has stumbled particularly in sub-Saharan Africa due to the direct and indirect 




About half of the 38 million people living with HIV in 2005 were women. Sixty three 
percent of these women lived in sub-Saharan Africa 
8
. The prevalence of HIV 
infection in antenatal clinics varied from 1% to 40%, the highest rates being in the 
same region 
9
. In 2003, the Western Cape region of South Africa registered an 
antenatal HIV seroprevalence of 12.4%. This rate was projected to increase in 
subsequent years
 10
. Additionally, HIV positive women are known to have a 9.5 times 
greater risk of maternal mortality than HIV negative women. The Saving Mothers 
report for the triennium 2005 – 2007 shows MMR was 327.7 per 100,000 livebirths in 
HIV positive compared to 34.4 per 100,000 livebirths in HIV negative women
2
. In the 





As such, HIV/AIDS has become the leading cause of maternal mortality in the sub- 
Saharan region, with the adult lifetime risk of dying in pregnancy and childbirth for a 





Although it is generally understood that most of the maternal deaths occur in the 
hospital setting, an uncertain proportion of such deaths occur outside the hospital and 
may also go unreported. In 1998, about 4% of the reported maternal deaths in South 
Africa occurred either at home or an unknown location
12
. This is an underestimate of 











focus on institutional deaths and do not seek to collect home deaths. In the most 
recent report looking at home maternal deaths in the Demographic Surveillance Area 
(DSA) in Hlabisa sub-district in northern Kwa-Zulu Natal Province, 23.1% - 63.5% of 
maternal deaths occurred at home
13
. Considering that death due to PPH takes place 
very rapidly once bleeding starts it is very likely that PPH contributes a sizeable 
proportion of the deaths taking place outside the health institutions. In addition, 
although as many as 91% of livebirths in South Africa are attended by a skilled birth 
attendant, there are strong urban/non-urban differences in the type of birth attendant. 
According to the South African Demographic and Health Survey (SADHS) of 2003, 
the proportion of births assisted by a doctor was higher (34%) in urban areas 




Women living with HIV/AIDS may be more susceptible to direct obstetric causes of 
maternal mortality such as PPH 
9
. This could be due to an increased incidence of PPH 
in HIV positive women due to the effect of the disease itself or its treatment. 
 
On the other hand, AIDS related anaemia may be an important factor, with these 
women presenting in labour with lower levels of haemoglobin and therefore not 
tolerating what would have otherwise been acceptable blood loss at delivery. 
 
HIV infection is also associated with impairment of other haematological indices such 
as platelets thereby predisposing the women to bleeding post partum. 















With increasing access to Prevention of Mother to Child Transmission of HIV  
(PMTCT) programmes as well as Highly Active Anti-Retroviral Therapy  
(HAART), the impact of the drug side effects of Zidovudine (AZT) and other  
anti-retroviral drugs on PPH has not been documented. AZT is known to cause  
pancytopenia with anaemia, thrombocytopenia and leukopenia the most observed 
17
. 
To date, no studies have been reported to evaluate the effect of HIV and its treatment  































2.1 Definition and Classification of PPH 
According to the 1990 World Health Organisation (WHO) definition, PPH is any 
blood loss from the genital tract more than 500ml during delivery. Caesarean 




There is great difficulty to measure PPH with accuracy. To date, there is no gold 
standard method to measure PPH. Though unreliable, clinical visual estimation of 
blood loss during delivery is a widely accepted method. 
 
In addition, defining PPH simply as blood loss greater than 500ml fails to take into 
account predisposing health factors that are reflected in such a definition. The quantity 
of blood loss is often less important than the actual effect that it has on the labouring 
woman. As such it has been suggested that the definition of PPH takes into account 
any blood loss that causes a major physiological change such as low blood pressure 




PPH is also classified by different methods. The objective of classifying PPH is three 
fold. Firstly, it helps to determine the urgency of intervention based on the rate of the 
patient’s deterioration due to the rapidity of progression of the bleeding.  
 
Secondly, classification helps in the assessment of the prognosis which may help to 
determine the intermediate, medium and long term clinical outcome. This also helps 











Thirdly, classification allows for standardisation of the estimated degree of 
haemorrhage which makes communication easier and more effective between health 
care personnel. 
 
A classification system that assesses volume loss in conjunction with clinical signs 
and symptoms should be the ideal in fully functional and well equipped hospitals and 
obstetric units. A perceived blood loss of 500ml to 1000ml in the absence of clinical 
signs of cardiovascular instability should be regarded as an alert line prompting basic 
measures of monitoring and readiness for resuscitation. 
 
A perceived blood loss of more than 1000ml or a smaller loss with clinical signs of 





































Clinical signs and 
symptoms 
0 (normal loss) < 500 < 10 None 
A                     L                        E          R               T 




A                      C                 T                   I                   O                 N 
 
2 
1200 – 1500 20 – 25 Decreased urine 






3 1800 – 2100  30 – 35    Hypotension, 
tachycardia, cold and 
clammy, tachypnea 















The control of bleeding post partum depends on primary mechanical events which are 
hormonally mediated to produce strong uterine muscular contraction. The powerful 
and prolonged contractions of the third stage of labour compress the spiral arteries 
while also helping to separate the placenta and membranes. 
 
Uterine atony accounts for 75% to 90% of primary PPH. This may be a result of a 
retained placenta or placental fragments which act as a physical impediment to uterine 
contraction
22,23
. In the third world setting, prolonged obstructed labour remains an 
important cause of uterine atony. It also contributes significantly to the number of 
cases of PPH following rupture of the uterus. In the triennium 2005 – 2007 in South 
Africa, uterine atony following prolonged labour accounted for 17.5% of all PPH 
deaths. On the other hand, ruptured uterus accounted for 20% of all deaths. Many of 




Overdistention of the uterus prior to delivery as the case may be with multiple 
pregnancy and polyhydramnios also affects the ability of the uterine muscle to 
contract effectively to arrest bleeding post partum. 
 
Furthermore, conditions such as leiomyomata increase the surface area for potential 
bleeding with tissue that is non contractile thus increasing blood loss. Antepartum 
haemorrhage secondary to abruptio placentae on the other hand may also predispose 
to postpartum haemorrhage due to poor uterine contraction as a result of impairment 














About 20% of primary PPH results from traumatic causes including obstetric 
lacerations, uterine inversion and rupture. Congenital and acquired clotting 




         
 
 
2.3 Prediction of PPH 
Severe primary PPH requiring blood transfusion can be predicted in the majority of 
patients by assessment of antenatal risk factors. In a study by Balki et al, assessment 
of antenatal risk factors predicted up to 61% of cases of PPH requiring blood 




Antenatal risk factors for PPH include maternal anaemia, multiple gestation, abnormal 
placentation, previous caesarean delivery, previous history of PPH due to uterine 
atony, fetal macrosomia, pregnancy induced hypertension, chorioamnionitis as well as 




Intrapartum risk factors include prolonged first stage of labour ( latent labour longer 
than 20 hours in nullipara or longer than 14 hours in multipara), cervical dilatation of 
less than 1.2cm per hour in nullipara or less than 1.5cm in multipara, prolonged 
second stage of labour ( more than 2 hours in nullipara without epidural or more than 
3 hours in nullipara with epidural or more than 1 hour in multipara without epidural or 
more than 2 hours in multipara with epidural) and a prolonged third stage of labour 












Labours that are induced or augmented with oxytocin are also associated with 




2.4 Role of anaemia in pregnancy
 
Anaemia is defined as the reduction in circulating haemoglobin mass below the 
critical level. WHO defines anaemia in pregnancy as a haemoglobin level less than 
11.0g/dL. In most developing countries, a lower cut off of 10.0g/dL is used to define 
anaemia. 
 
Anaemia in pregnancy can be classified as mild, moderate, severe and very severe 




Class of anaemia                                         Haemoglobin level (g/dL) 
 
Mild                                                              9 – 11  
Moderate                                                      7 – 9  
Severe                                                           4 – 7  
Very severe                                                   < 4 
 
Anaemia in pregnancy can be physiological or acquired. Physiological anaemia in 
pregnancy occurs as a result of a disproportionate increase in plasma volume 
compares to red blood cell mass resulting in a drop in haemoglobin level. 
 
Iron deficiency anaemia accounts for almost 60% of all cases of acquired anaemia in 











acid and/or Vitamin B12 deficiency, dimorphic and protein deficiency anaemia which 
is both due to deficiency of iron and folic acid and/or vitamin B12 and protein 





Severe anaemia in pregnancy may predispose to high output cardiac failure, infection 
and inability to withstand what would otherwise be normal blood loss during delivery. 





In a study by Hoque M et al, the prevalence of anaemia in a rural population of 
Kwazulu Natal was found to be 30% according to the national definition of 10.0g/dL. 




Worldwide rates of anaemia in pregnancy range from 30% to 70%
31
. In 2000, 





Anaemia in pregnancy is a well known risk factor for many maternal and 
fetal/neonatal complications. Maternal complications include poor weight gain, 
preterm labour, pregnancy induced hypertension, placenta previa, eclampsia and 












Intrapartum, anaemia can result in dysfunctional labour, antepartum haemorrhage, 
shock, cardiac failure as well as anaesthethic risks
31
. Post partum, anaemia may 
predispose to PPH, sepsis, uterine sub-involution and embolism. 
 
Fetal/neonatal complications include prematurity, poor Apgar scores, fetal distress 
requiring neonatal resuscitation, neonatal anaemia due to poor reserve and low birth 
weight. Anaemia in pregnancy is also associated with adverse behavioural and 





The effects of anaemia in pregnancy may be extended into adult life of the affected 
fetus. Children exposed to anaemia in the first trimester of pregnancy have higher 
rates of cardiovascular morbidities and mortality than those of non anaemia in 
pregnancy children. 
 
Death from anaemia is a result of heart failure, shock or infection since the patient 
develops an impaired immune status. Less severe anaemia contributes to morbidity 
and mortality from PPH due to the fact that anaemic women do not tolerate blood loss 
as well as healthy women and are therefore more likely to die from haemorrhage. 
 
About 20% of the maternal deaths in sub-Saharan Africa are associated with anaemia 
in pregnancy
35,36
. Infection with the Human Immunodeficiency Virus (HIV) is also a 
known risk factor for anaemia. This may be a result of enhancement of nutritional 
















2.5 Complications of PPH 
Massive obstetric haemorrhage especially PPH is responsible for up to 25% of 
maternal deaths worldwide
1
. In developing countries, PPH may be responsible for as 
many as 28% of maternal deaths. 
 
The risk of maternal death increases with advancing maternal age particularly for 
those women aged 35 years and above. Massive haemorrhage with coagulopathy also 
significantly increases the risk of dying. 
 
Other direct maternal consequences of major blood loss include hypovolaemic shock 
characterised by persistent severe hypotension defined as a systolic blood pressure 
<90mmHg with a pulse rate of at least 120 beats per minute
40
, disseminated 
intravascular coagulation and hepatic failure presenting with coagulopathy with 
elevated international normalized ratio (INR) and prolonged activated partial 
thromboplastin time (aPTT) and deranged liver function, acute renal failure manifest 
as oliguria/anuria and elevated blood urea and creatinine
41
, Sheehan’s syndrome and 




Severe PPH with haemorrhagic shock has been found to be associated with 
myocardial ischemia. In a study by Karpati et al, 51% of 55 women admitted for 
severe PPH had elevated serum levels of cardiac troponin I which were also 
















2.6 Complications arising from the management of PPH 
The administration of large amounts of intravenous fluids and blood products to 
correct hypovolaemia predisposes patients with PPH to fluid overload and left 
ventricular failure. Such complications may be severe enough to warrant admission to 
intensive care unit with intubation and ventilation as well as invasive haemodynamic 
monitoring. 
 
Surgical procedures to stop bleeding are also associated with certain complications. 
Evacuation of the uterus to remove retained products of conception may be 
complicated by perforation of the uterus. Over curettage may also give rise to 
Asherman’s syndrome. 
 
Brace procedures such as the B-Lynch and modified B-Lynch sutures placed to 
compress an atonic uterus may result in direct trauma to the bladder, ureters, and 
bowel. 
 
Despite overall good reports of success following stepwise uterine devascularization 
and arterial embolization, isolated cases of maternal death have been reported 
following such procedures. In a series of 49 cases of bilateral hypogastric artery 
ligation, Ledee et al reported success rates of up to 90%. Failure of the procedure was 
















On the other hand, complications of selective arterial embolization include post 
procedure fever, feet ischaemia, bladder and rectal wall necrosis and sciatic nerve 




Pelage et al, in an evaluation of 35 patients who underwent selective arterial 
embolization reported one case of re-bleeding occurring 5 days after the procedure 




Hysterectomy is a life saving procedure when all other measures to control bleeding 
have failed. A subtotal hysterectomy is often sufficient if bleeding originates from the 
upper segment of the uterus. It is associated with less need for blood transfusion and 
reduced intra-operative and post-operative complications
44,47
. However, a total 
abdominal hysterectomy is indicated if bleeding is from the lower uterine segment or 
the uterine cervix. Complications that may arise from a hysterectomy include 




Surgery for PPH may be complicated by sepsis. The risk of sepsis is compounded by 
the patient’s HIV status as well as the stage of disease. Common sites of infection are 
the wound site, respiratory tract and the urinary tract. These patients may also be 











According to the Saving Mothers report of 2005 – 2007, the biggest cause of maternal 
mortality was non pregnancy related infections of which AIDS was the predominant 




2.7 HIV and haematology 
Advanced HIV disease with profoundly low CD4 count is associated with the  
development of thrombotic microangiopathy. These patients may present with  
haemolytic anaemia and thrombocytopenia. 
 
Patients with HIV associated thrombotic microangiopathy are also thought to have a  
smouldering disseminated intravascular coagulation and may benefit from plasma 




Thrombocytopenia is thought to be secondary to HIV infection of megakaryocytes  





CD4, which is the receptor for HIV on T cells has also been demonstrated on 
megakaryocytes thus indicating that those cells can also be infected with HIV
52,53
.  
Endothelial cells are also infected with HIV leading to endothelial injury.  As such,   





















 is considered to constitute thrombocytopenia. Spontaneous 







 are associated with post traumatic bleeding. 
Platelet counts of less than 50,000/mm
3
 are associated with an increased risk of 




Typically, bleeding associated with thrombocytopenia is associated with prolonged 




2.8 The coagulation cascade 
Platelets have a central role in normal haemostasis. On contact with extracellular 
matrix following vascular injury, platelets undergo three general reactions of adhesion 
and shape change, secretion and aggregation. 
 
The adhesion of platelets to the extracellular matrix is largely mediated via interaction 
with von Willebrand’s factor (vWF). vWF acts as a bridge between platelet surface 




Such interaction stabilizes the initial platelet adhesion against the high shear forces of 
flowing blood. The process by which platelets facilitate clot formation are 
summarised in the steps below
59
. 
1. Platelets adhere to extracellular matrix at sites of endothelial injury and 
become activated. 
2. On activation, platelets secrete granule products such as adenosine 











3. Platelets also expose phospholipids complexes important in the intrinsic 
coagulation pathway. 
4. Injured or activated endothelial cells expose tissue factor which triggers the 
extrinsic coagulation cascade. 
5. Released ADP stimulates formation of a primary haemostatic plug which is 
eventually converted (via ADP, thrombin and TXA2), into a large definitive 
secondary plug. 
6. Fibrin deposition stabilizes and anchors the aggregated platelets. 
 
2.9 Association between HAART and bleeding 
It is well known that the mainstay for treatment of patients infected with HIV is the 
use of HAART. However, treatment with these drugs is not without side effects. 
 
HIV protease inhibitors have been found to cause spontaneous bleeding in patients  
with haemophilia. In a study comparing the protease inhibitors ritonavir, indinavir and 
saquinavir with zidovudine among HIV positive haemiphiliacs, more episodes of 
bleeding were reported in patients on protease inhibitors (58%) compared to 
zidovudine (3.2%). 
 
This effect was also found in non haemophiliacs. Of the 6035 reports for indinavir, 
saquinavir and ritonavir to the FDA’s spontaneous adverse event reporting system by 
28 February 1997, 161(2.7%) were for bleeding. Similarly, 2.6% (71 of 2718) of 
reports for zidovudine were for bleeding. These reports were for both haemophiliacs 












It is important to note that in all the cases described, there was no report on uterine 
bleeding. Common sites of bleeding for haemophiliacs included skin/soft tissue and 
joints. On the other hand, for persons without haemophilia, bleeding predominantly 
occurred in the gastrointestinal tract and mucus membranes. There was also a 




2.10 Prevention of mother to child transmission of HIV (PMTCT) 
The consecutive Saving Mothers reports for triennia 1999 – 2001, 2002 – 2004 and 
2005 – 2007 all show non pregnancy related infections to be the leading cause of 
institutional maternal death in South Africa. The biggest majority of these infections 
(23.1% in 2005 – 2007) are from AIDS
2,3,61
. The importance of the PMTCT program 
in South Africa can therefore not be overemphasized. Initially this program was 
primarily aimed at reducing the rates of HIV transmission from the mother to her 
unborn child. However with time the program has evolved to incorporate 
comprehensive care for those women with CD4 counts of less than 350cells/mm
3
 who 
benefit from expedited initiation of lifelong treatment with highly active antiretroviral 
drugs. Such an approach is expected in the long term to help reduce the burden of 





The PMTCT program is a comprehensive program that works on four important 
elements namely: 
 Primary prevention of HIV especially among women of childbearing age 
 Preventing unintended pregnancies among women living with HIV 











 Providing appropriate treatment, care and support to women living with HIV 
and their children and families. 
To attain these goals, the National Department of Health of South Africa produced 
revised (2010) guidelines for the prevention of mother to child transmission of HIV. 
In these guidelines, all women presenting for antenatal clinic are offered HIV 
counselling and testing
62
. This protocol was fully implemented in the Western Cape in 
October 2010. 
Below is an algorithm showing this provider initiated counselling and testing (PICT). 
                                                  Group information 
                                                           Session 
 
 
                                             Individual information session 
                                             For each woman and offer to test 
 
 
                    Agree to test                                                                 refuse to test 
 
 
HIV negative                               HIV positive                           post refusal counselling 
                                              (confirm by 2
nd
 rapid test) 
 
 
Post test counselling                  counselling, same day CD4       continuous PICT with 











HIV positive women with CD4 count > 350 are started on Zidovudine at 14 weeks 
gestation. Those with a count of 350 and below or those with clinical HIV disease 
stage 3 or 4 are started on lifelong antiretroviral therapy (ART) within 2 weeks of 
diagnosis. Patients with an initial negative test result are offered a repeat test at 32 
weeks to identify those that develop seroconversion during their pregnancy and offer 
them appropriate treatment.  
 
During labour and delivery, women on Zidovudine receive 3 hourly Zidovudine until 
delivery and single dose Nevirapine at the onset of labour as depicted in the algorithm 
below. 
HIV positive mother                                              single dose nevirapine at onset of 
On Zidovudine or without                                     labour and 3 hourly Zidovudine until 
treatment                                                              delivery 
 
                                                                               Single dose Tenofovir and                
                                                                               Emtricitabine (Truvada) after  
                                                                               delivery. Assess for lifelong 
                                                                               ART before discharge 
 
                                                                                
 
       infant receives Nevirapine for  
                                                                               6 weeks or for duration of breast 
                                                                               feeding 
 
Mother on lifelong ART                                       continue ART regimen throughout                                                                                                                
                                                                               Labour and beyond 
                                            
       Infant receives nevirapine for 











Identification of HIV positive women through the PMTCT program therefore 
facilitates identification of women at risk of morbidity and mortality from PPH and 
other HIV associated causes of maternal morbidity and mortality. 
 
Prior to the 2010 revision of the PMTCT guidelines, HIV positive antenatal women 
were started on Zidovudine 300mg 12 hourly at 28 weeks gestation. They received 
single dose Nevirapine at the onset of labour and 300mg Zidovudine 3 hourly while in 
labour. Women with CD4 count less than 200/mm
3
 or Stage IV disease were 
recommended for immediate commencement of highly active antiretroviral therapy. 




2.11 Haematological antiretroviral side effects 
According to the 2010 PMTCT guidelines formulated by the National Department of 
Health of South Africa, the most commonly used antiretroviral drugs for those women 
with CD4 count more than 350 cells/mm
3
 are Zidovudine and Nevirapine . 
 
For women requiring lifelong ART, the first line regime comprises a combination of 
Tenofovir, Lamivudine/Emtracitabine and Nevirapine. Zidovudine is used in place of 
Tenofovir if the latter is contraindicated as the case may be in patient with renal 
disease. Patients on lifelong ART comprising Efavirenz prior to pregnancy are 
switched to Nevirapine in the first trimester. If however such patients present after the 



















       eosinophilia 
b. Tenofovir: decreased neutrophils in up to 3% of cases 
c. Efavirenz: neutropenia (less than 750/mm3) in up to 10% of cases. It also 
      rarely causes haemolytic anaemia. 
d. Truvada: neutropenia in up to 3% of cases 
e. Lamivudine: bone marrow toxicity in doses up to 20mg/kg/day. Neutropenia  
      (7.2%), anaemia (2.9%) and thrombocytopenia (0.4%) has been reported when      
      it is used with zidovudine. 
f. Zidovudine: Anaemia (Hb<8g/dL) in 1% of patients and granulocytopenia    
      (<750cells/mm
3
 ) in 2% of patients.  
 
2.12 PPH and blood transfusion 
Transfusion of blood components plays a central role in the management of life 
threatening haemorrhage. It is a life saving procedure and an important criteria of 




In a study by Balki et al, the rate of blood transfusion for PPH was 0.31%. 0.49% of 
women undergoing a caesarean section during labour had PPH requiring blood 
transfusion while those women undergoing a normal vaginal delivery had a 
transfusion rate of 0.28%. The rate of blood transfusion for PPH following elective 




A larger study of 57,000 deliveries by Rouse et al showed a 3.2% transfusion rate for 
women undergoing primary caesarean section and 2.2% for those undergoing repeat 
















Transfusion of blood products is not without risk. Such risks include transmission of 
infectious diseases such as HIV and hepatitis B and C, transfusion reactions and 
alloimmunisation. It is also associated with significant cost to both the patient and the 
health care system. 
 
In the USA, the risk of HIV transmission per unit of blood transfused is 1 in 450,000 
to 1 in 660,000. This risk may be higher in the South African setting due to the high 





Over the years, rates of blood transfusion have decreased due to improved prevention, 
surveillance and treatment of PPH. This is shown in the studies by Klapholz and 





Recognizing the magnitude of the problem of PPH in South Africa, the national 
committee for the confidential enquiries into maternal deaths (NCCEMD) developed 
a handbook of PPH management to help health care workers at all levels of care to 
recognize and rapidly institute measures to deal with life threatening haemorrhage
69
. 
The overview of the 4
th
 Saving Mothers report (Chapter 1) indicates that MMR from 













. However if HIV infection is associated with PPH or PPH 
mortality then this may also be a factor in why MMR from PPH has not diminished. 
 
2.13 Problem statement and hypothesis 
PPH as a cause of maternal death is increasing in South Africa and, according to the 
Saving Mothers 2005-2007 report on maternal deaths, the maternal mortality ratio due 
to PPH is higher in HIV positive than HIV negative women. This raises questions as 
to whether this is a real increase or an artefact due to misclassification of causes of 
death. If it is a real effect, is this due to an increase in the incidence of PPH in HIV 
positive women, or an increase in morbidity from PPH due to co-morbidities such as 
anaemia associated with HIV, or could it be an effect of ARV medications? 
 
The aetiology of PPH in HIV positive women may be multi-factorial and may differ 
between patients who are on highly active antiretroviral therapy and those who are 
treatment naïve. In poorly resourced settings where HIV seroprevalence is high  
among reproductive age women and maternal mortality from PPH is also common,  
iron deficiency anaemia and HIV associated anaemia and/or thrombocytopenia may  
be the most important factors affecting both the incidence and severity of PPH. 
 
On the other hand, although the literature does not indicate any cases of haemorrhage 
associated with treatment with HAART, evidence from the field of haematology  
suggests that certain medications such as protease inhibitors predispose to bleeding. 
This may also apply in pregnancy and childbirth. 
 











positive women compared to HIV negative women may be as a result of  
misclassification of the causes of maternal death from less experienced maternal death  
assessors especially in the rural areas. As such, HIV infection may in fact not be 
associated with increased mortality from PPH. 
 
It is against this background of the reported increased mortality from PPH among HIV 
positive women compared to HIV negative women that this study set out to 
investigate whether HIV seropositivity is associated with an increase in the incidence 
and severity of PPH to justify the apparent increased mortality. 
 
The hypothesis being tested was that PPH is more common and more severe among 

























Aim of the study 
The main aim of the study was to investigate the relationship between HIV infection 
and the incidence and severity of postpartum haemorrhage in women delivering at 
Mowbray Maternity and Groote Schuur Hospitals in 2009. 
 
Specific objectives 
1. To establish the incidence of PPH in HIV positive women compared to HIV  
      negative women. 
2. To describe the causes of PPH in HIV positive women compared to HIV    
      negative women. 
3.  To determine the severity of and morbidity associated with PPH in HIV  
      positive women compared to HIV negative women. 
     4.   To compare the severity of PPH and morbidity from PPH with respect to 
            age, parity, BMI, mode of delivery, HIV seropositive status and mean haemoglobin 
      level on admission for delivery. 
5.  To describe the characteristics of HIV positive women with PPH with  
            respect to CD4 count at booking, the nature of Antiretroviral Therapy and  
            the duration of treatment.  



















4.1 Study Design 
The study design was a retrospective cross-sectional analytic study of all cases of 
postpartum haemorrhage occurring at Mowbray Maternity and Groote Schuur 
Hospitals from 1 January 2009 to 31 December 2009.  
 
4.2 Inclusion Criteria 
Women who experienced blood loss more than 500ml following delivery of a fetus 
weighing more than 500 grams or gestational of 24 weeks or more were identified for 
the study. The recorded blood loss was based on clinical estimation by the attending 
health care provider at the time of delivery. Only patients who delivered at Mowbray 
Maternity and Groote Schuur Hospitals during the study period were included in the 
study. 
 
The choice of 500ml of blood loss as the cut-off for the definition of PPH was based 
on three factors. Firstly, the use of visual estimation to quantify blood loss may result 
in significant underestimation of blood loss. As such an estimated blood loss of 500ml 
may be accompanied by significant physiological effects with hypotension and 
tachycardia. 
 
Secondly, in a population where the prevalence of anaemia is high such as is the case 
in South Africa, blood loss of 500ml or more may result in significant adverse 












Thirdly, although critical of the low threshold of 500ml for PPH, the cited literature 
used the same cut-off as proposed by the World Health Organization in 1990 to define 
PPH
1,17,22
. In order to maintain uniformity with available literature, blood loss of 
500ml or more at the time of delivery was therefore used to define PPH in this study. 
 
4.3 Study Population 
The Metro West maternity service comprises one tertiary hospital, two secondary 
hospitals and ten primary care obstetric units. The flow chart below outlines the 
obstetric care units and their route of referral. 
Primary Facility                        Secondary Hospital                   Tertiary Hospital 
LABU 
Gugulethu MOU                         Mowbray Maternity     
Khayelitsha MOU 
Mitchells Plain MOU  
                                                                                                                Groote Schuur 
Vanguard MOU 





False Bay Hospital 
Referral criteria for the different levels of care are clearly outlined and are accessible 
to all health care workers in the different facilities. Emergency referrals are triaged by 











appropriate level of care as well as type of ambulance transfer depending on severity 
and urgency of the reason for referral. Three categories of ambulance transfer are in 
place namely ordinary ambulance, urgent ambulance and flying squad. Primary level 
midwife obstetric units refer all women with post-partum haemorrhage to their 
referral hospital by flying squad. 
 
The study was conducted on deliveries at Mowbray Maternity and Groote Schuur 
Hospitals, thus including women who had been referred antepartum or intrapartum to 
the two hospitals from satellite MOUs. It was originally intended by the investigators 
to conduct the study on all deliveries in all the health facilities of the Metro West area 
for the year 2009. However due to time constraints to meet deadlines for submission 
of the completed work, this was not achievable. The selection of the two hospitals as 
study sites was based on convenience and in recognition that the majority (89%) of 
cases of PPH in the Metro West occur at the hospitals rather than the MOUs due to 
the prompt system of referrals from the MOUs of women at risk for PPH (eg with 




4.4 Patient Identification 
The names and folder numbers of patients who delivered at the two hospitals and had 
PPH were retrospectively identified by a physical review of the labour ward and 
theatre registers at Mowbray Maternity Hospital and at Groote Schuur Hospital. 
  
Once a case of PPH was identified, the patient’s hospital folder was retrieved from the 
records department in the health facility for a review of the patient’s booking 











Information about labour and delivery including duration, mode of delivery, amount 
of bleeding and interventions instituted among other things were also recorded on a 
Microsoft Excel formulated data collection sheet (Appendix 1). 
 
Severity of bleeding was classified according to a modification of the proposed 
classification described in Table (i) as follows: 
            Severity                                               Amount of blood loss (ml) 
              Mild                                                        500 – < 1200 
              Moderate                                              1200 – < 1800   
              Severe                                                   1800 – < 2400  
              Very severe                                           2400 or more 
Such modification was necessary in order to set clear cut offs for each of the severity 
classes. In addition, the need for blood transfusion, hysterectomy and mechanical 
ventilation were used as markers of severe morbidity. A morbidity score was assigned 
following internationally accepted guidelines depending on the presence of certain 




Severe                            lowest recorded haemoglobin of 6g/dL or less, transfusion of  
                                       5 or more units of packed cells or whole blood, transfusion of     
                                       any other blood products such as fresh frozen plasma,  
                                       platelets and cryoprecipitate, hypovolaemic shock, admission      
                                       to ICU, need for mechanical ventilation, any organ failure 
                                       or need for an emergency hysterectomy. 
 











                                      transfusion of up to 4units packed cells or whole blood,  
                                      placement of B- Lynch suture and placement of an intrauterine  
                                      catheter for balloon tamponade 
 
No morbidity              when none of the above occurred. 
 
4.5 Data Collection 
Data was entered on a standard data collection sheet specifically designed for the  
study (Appendix 1). Delivery records from the cradle software were accessed for 
purposes of quantifying the total number of deliveries that took place during the study 
period in the two hospitals. 
 
HIV registers were also reviewed in the two health facilities involved to quantify 
the proportion of delivered women who were HIV positive, negative, untested and 
those who declined testing. 
 
4.6 Data analysis 
Descriptive data were analysed by using Microsoft Excel Statistical package.  This 
package was used to calculate frequencies and proportions, means and median parity.  
 
Stata software package version 10.1 was used for significance testing of the observed 
differences in the different variables between HIV positive and HIV negative women. 
Odds ratios were calculated using this statistical package with a 95% confidence 












The t-test mean comparison test was used to test for statistical significance of the 
difference between means. 
 
The power for this cross-sectional study was calculated using the OpenEpi, version 2 
open source calculator based on normal approximation. A two-sided confidence 
interval of 95% was used. The exposed group comprised HIV positive women while 
the non-exposed group comprised HIV negative women and the occurrence of PPH as 
the outcome of interest. 
 
4.7 Sample size 
The study planned to include all deliveries complicated by PPH occurring at 
Mowbray Maternity and Groote Schuur Hospitals during one calendar year from 1
st
 
January 2009 to 31
st
 December 2009. A sample size calculation was performed to 
ascertain whether data for this duration would be sufficient to determine a statistically 
significant difference in the incidence of PPH between HIV positive and HIV 
negative women delivering at the two hospitals.  
 
The sample size calculation was based on the observation that the maternal mortality 
ratio from PPH in South Africa during the triennium 2005 – 2007 in HIV positive 
women was almost three times as high as that of HIV negative women (13.7 vs 5.7 
per 100,000 live births)
2
. In addition the PPH rate at MMH and GSH in previous 
years was 10% for all deliveries (HIV positive and HIV negative women combined).  
An assumption was made for the current study that the proportion of HIV positive 
women with PPH delivering at the two hospitals would be 15% of all the deliveries 












In order for the study to have a power of at least 80% to determine a statistically 
significant difference (95% confidence) in the incidence of PPH between HIV 
positive and HIV negative women, a minimum sample size of 432 women with PPH 
was required. 72 of these needed to be HIV positive and 360 women needed to be 




Before proceeding with the study, ethics approval was obtained from the  
University of Cape Town ethics committee. Permission was also obtained from the 


























Mowbray Maternity Hospital and Groote Schuur Hospital registered a total of  
15384 deliveries in 2009. 2738 (17.8%) of these deliveries were HIV positive, 12151 
(79.0%) HIV negative and 495 (3.2%) HIV untested. The untested group included 
women who declined testing and those who were unbooked at the time of delivery 
and therefore untested. 
 
A total of 1230 (8.0%) women had recorded blood loss of 500ml or more at the time 
of delivery. 270 of these women (22%) were HIV positive, 915 (74.4%)  were HIV 
negative and 45 (3.6%) were HIV untested. 
 
5.1 The rate of PPH in HIV positive compared to HIV negative women 
Out of the 2738 HIV positive deliveries at the two hospitals in 2009, 270 (9.9%) had 
PPH. On the other hand, 915 of the 12151 HIV negative deliveries (7.5%) had PPH. 
The difference in the mean blood loss between HIV positive and HIV negative 




















PPH rate and mean blood loss in HIV positive and HIV negative women. 
PPH rate in HIV 
positive compared 














PPH rate 270 (9.9%) 915 (7.5%) 45 (9.1%) 1.34 
(1.16 – 1.55) 
0.001 
Mean blood loss 
(ml) 
736 725 858  0.697 
*Odds Ratios and P values comparing HIV positive with HIV negative group 
      
These findings give this cross-sectional analytic study the power of 98.74% based on 






















5.2 Demographic, pregnancy and labour details of HIV positive women with 
PPH compared to HIV negative women with PPH (Table 2) 
The mean age in the three groups of women was 28 years and the median parity was 
1. Of the 906 women whose body mass index (BMI) was measured at the time of 
antenatal care booking, 51% had BMI of more than 30kg/m². Amongst the HIV 
positive women with PPH, there was a significantly lower proportion of women aged 
35 years or more; and BMI greater than 36kg/m
2
 when compared to HIV negative 













































 Up to 18 
19 to 35 

















0.555 (0.26 – 1.08) 
2.670 (1.71 – 4.33) 
0.327 (0.17 – 0.58) 
 0.738 






1.12 1.19 1.00  - 0.398 
BMI 
  up to 30  
  31 to 35 























1.273 (0.95 – 1.69)  
1.406 (0.99 – 1.98) 
0.572 (0.38 – 0.85) 







































1.323 (0.86 – 1.81) 
0.841 (0.35 – 1.81) 







GA at delivery 
 a. < 34 weeks 























10.7 10.8 10.3   0.627 
*Odds Ratios and P values comparing HIV positive with HIV negative 











There was no difference in the level of haemoglobin at the time of admission for 
delivery between the HIV positive and HIV negative women who had PPH (Table 2). 
 
Table 3 compares pregnancy and labour complications in HIV positive and negative 
women with PPH. Hypertension was significantly less common as a pregnancy 
complication in HIV positive women with PPH compared to HIV negative. 
Hypertension was defined as any rise in blood pressure of 140/90 mmHg or more on  
at least two occasions at least six hours apart at any gestation with or without the 
presence of proteinuria. There was no difference in the incidence of complications 
such as cephalopelvic disproportion, fetal distress, twin gestation, abruptio placentae 
and placenta previa in HIV positive women with PPH compared to HIV negative 


























The incidence of other pregnancy/labour complications in HIV positive women with 













Hypertension 24 (8.9%) 149 
(16.3%) 
8 (17.8%) 0.50 





25 (9.3%) 90 (9.8%) 4 (8.9%) 0.56 
(0.56 – 1.51) 
0.91 
Twins 18 (6.7%) 57 (6.2%) 1 (2.2%) 1.08 
(.58 – 1.89) 
0.77 
Fetal distress 43 (17.9%) 169 
(18.5%) 
4 (8.9%) 0.84 




19 (7.0%) 73(8.0%) 8 (17.7%) 0.87 




2 (0.74%) 3 (0.33%) 2 (4.4%) 2.27 
(0.19 – 19.89) 
0.32 
*Odds Ratios and P values comparing HIV positive with HIV negative 
   group 
 
Table 4 shows the mode of delivery by HIV status of all the women who had a PPH. 
Seven hundred and thirty-three (60%) of the women with postpartum haemorrhage 
were delivered by emergency caesarean section. 276 (22.4%) had elective caesarean 











vaginal delivery with vacuum extraction, 4 women had forceps delivery and 6 had 




















Elective c/s 61 (22.6%) 206 
(22.5%) 
9 (20.0%) 1.004 






551(60.2%) 24 (53.3%) 0.93 
(0.70 – 1.24) 
0.62 
NVD 49 (18.1%) 139 
(15.2%) 
10 (22.2%) 1.24 
(0.85 – 1.79) 
0.255 
Breech 0 (0.0%) 5 (0.55%) 1 (2.2%) - - 
Forceps 1 (0.37%) 3 (0.33%) 0 (0.0%) 1.13 
(0.21 – 14.14) 
** 
Vacuum 1 (0.37%) 10 (1.1%) 1 (2.2%) 0.34 
(0.01 – 2.39) 
** 
Laparotomy 0 (0.0%) 1 (0.11%) 0 (0.0%) - - 
*Odds Ratios and P values comparing HIV positive with HIV negative group 












Among the women with PPH who had emergency caesarean sections, the mean blood 
loss was higher in HIV positive compared to HIV negative women. HIV negative 
women delivering vaginally, however, had a significantly higher mean blood loss than 
HIV positive women (Table 5). 
 
Table 5 
Mean blood loss by mode of delivery for HIV positive and negative women with PPH 












Elective c/s 670 697 711 0.651 
Emergency c/s 762 695 800 0.067 
NVD 744 878 1135 0.049 
Vacuum 500 810 500 ** 
Forceps 500 900 - ** 
Breech - 690 1200 - 
*P value comparing HIV positive with HIV negative group 
** numbers were too small for comparison between the HIV positive and HIV negative group 
 
5.3 Causes of PPH in HIV positive women compared to HIV negative women 
Uterine trauma at caesarean section was the most common cause of postpartum 
haemorrhage in all the three groups of women. This was bleeding from the uterine 
incision or its extension whether intended or accidental which required extra suturing 
other than the standard two layer closure. Such trauma included tears extending from 











among others. Other causes of post-partum haemorrhage included uterine atony, 
abruptio placentae, retained placenta, retained products of conception and ruptured 
uterus (Table 6). Not uncommonly, more than one cause of PPH was ascribed to a 
case of PPH. As such, the numbers add up to more than the total for the column (n). 
 
Table 6 













Atony  81 (30.0%) 268 
(29.3%) 
13 (28.9%) 1.03 








29 (87.9%) 1.50 




4 (7.8%) 26 (16.6%) 0 (0.0%) 0.429 




4 (1.5%) 11 (1.2%) 1 (2.2%) 1.23 




19 (3.3%) 73 (8.0%) 8 (17.8%) 0.87 




1 (0.37%) 9 (0.98%) 1 (2.2%) 0.37 
(0.01 – 2.72) 
0.471 
*Odds Ratios and P values comparing HIV positive with HIV negative group 
**Total number of caesarean sections used as denominator 












5.4 Treatment provided for PPH in HIV positive compared to HIV negative 
women 
Following the diagnosis of PPH, interventions instituted depended on the cause as 
well as the severity of the bleeding. Such interventions ranged from medical 
management with uterotonics to surgical procedures for specific causes. Some women 
also required the administration of blood products. Tables 7 to 9 outline the different 
interventions that were instituted. 
Table 7 
















58 (21.5%) 258 
(28.2%) 
7 (15.6%) 0.69  
(0.49 – 0.97) 
0.028 




23 (51.1%) 1.24 
(0.94 – 1.65) 
0.124 
Oxytocin + ergometrin 
only 
5 (1.9%) 9 
(0.98%) 
1 (2.2%) 1.89 
(0.50 – 6.37) 
0.331 
 
Oxytocin + misoprosol 
only 
62 (23.0%) 203 
(22.2%) 
11 (24.4%) 1.04 




9 (3.3%) 33 
(3.6%) 
2 (2.4%) 0.92 
(0.38 – 2.00) 
1.00 
 
Other + Prostaglandin 
F2alpha 
7 (2.6%) 24 
(2.6%) 
1 (2.2%) 0.98 
(0.36 – 2.40) 
1.00 



























3 (1.1%) 17 (1.9%) 1 (2.2%) 0.59 




4 (1.5%) 21 (2.3%) 2 (4.4%) 0.64 
(0.16 – 1.92) 
0.629 
**Suturing  207 (94.5%)  677 (89.4%) 25 (75.8%) 2.04 




5 (9.8%) 28 (17.8%) 3 (25%) 0.50 




3 (5.9%) 8 (5.1%) 0 (0.0%) 1.16 
(0.19 – 5.10) 
0.733 
**B Lynch suture 12 (5.5%) 36 (4.8%) 0 (0.0%) 1.16 




3 (1.1%) 6 (0.66%) 0 (0.0%) 1.70 
(0.27 – 8.03) 
0.433 
Hysterectomy 1 (0.37%) 3 (0.33%) 0 (0.0%) 1.13 
(0.21 – 14.14) 
1.00 
*OR and P value comparing HIV positive and HIV negative group 
  **Suturing includes repair of extensions of the uterine incision, uterine tears extending from the 
incision, suturing of bleeding points from the dissection of adhesions on the anterior uterine wall and 
figure of 8 sutures for bleeding points along the incision following a 2 layer closure among others. 
Total number of caesarean sections in each HIV group was used as the denominator for this 
intervention since the interventions only took place during caesarean delivery. 
*** Total number of vaginal deliveries was used as the denominator for these interventions since these 












Blood products for the management of PPH 











       0 
 
       1 – 4 units 
 





















(0.70 – 1.43) 
1.00 
(0.68 – 1.46) 
1.00 









15 (5.6%) 51 (5.6%) 10 (22.2%) 0.99 
(0.51 – 1.84) 
1.00 
Cryoprecipitate 0 (0.0%) 4 (0.44%) 2 (4.4%) - - 
Platelets 3 (1.1%) 6 (0.66%) 3 (6.7%) 1.70 
(0.27 – 8.03) 
0.43 
 
*Odds Ratios and P values comparing HIV positive with HIV negative group 
 
5.5 The severity of and morbidity associated with PPH in HIV positive women 
compared to HIV negative women 
Table 10 shows the complications associated with PPH in HIV positive and HIV 
negative women. More HIV positive women had a lowest haemoglobin level of more 
than 10g/dL following PPH compared to HIV negative women, and a significantly 
higher proportion of HIV positive women had mild anaemia (Hb >6g/dL to 10g/dL) 











A higher proportion of HIV negative women (2.6%) had documented hypovolaemic 



































Complications associated with PPH 













a. No anaemia 
 
b. Hb > 6 – 10 
 
c. Hb 6 or less 
 
 






















(0.52 – 0.97) 
1.55 
(1.15 – 2.10) 
0.638 












































































Table 11 shows a comparison of the severity of PPH between HIV positive and HIV 
negative women. The severity of postpartum haemorrhage, defined by the estimated 
amount of blood lost at the time of delivery was not affected by the HIV status. 
 
Table 11 
Severity of PPH in HIV positive women with PPH compared to HIV negative women 
with PPH 










Mild  240 (90.7%) 820 (89.6%) 35 
(77.8%) 
0.926 
(0.59 – 1.48) 
0.735 
Moderate 25 (9.3%) 72 (7.9%) 7 
(15.6%) 
1.19 
(0.71 – 1.95) 
0.45 
Severe 2 (0.7%) 12 (1.3%) 3 (6.6%) 0.56 
(0.61 – 2.55) 
0.748 
Very severe 3 (1.1%) 11 (1.2%) 0 (0.0%) 0.803 
(0.16 – 3.53) 
0.441 
*Odds Ratios and P values comparing HIV positive with HIV negative group 
 
Table 12 below shows a comparison of the severity of PPH in relation to maternal 
age, parity, BMI, mode of delivery, HIV status and mean haemoglobin level at the 
time of admission to labour ward or prior to caesarean section. To simplify the table, 
the severity of PPH was divided into two categories of ‘mild’ and ‘moderate to 
severe’ depending on whether blood loss was less than 1200ml or 1200ml or more 











and HIV status when all women with mild PPH were compared with all women with 
moderate/severe PPH. 
 
There was a significantly higher proportion of women with mild PPH (84.8%) who 
had a caesarean section compared to women with moderate/severe PPH (60.7%). 
Significantly more women with moderate/severe PPH  had  a lower haemoglobin 
concentration at the time of admission to labour ward or prior to caesarean delivery 





























Table 12  
Comparison of severity of PPH with respect to age, parity, BMI, mode of delivery, HIV 
seropositive status and mean haemoglobin level on admission for delivery. 










Mean age (yrs) 27.62 28.15  0.37 
Age group (yrs) 
Up to 35 
































    Up to 35 
   36 and above 











(0.386 – 1.31) 
 
*0.346 
























(0.592 – 1.48) 
**0.736 
Mean Hb (g/dl) 10.95 9.58  0.00001 
* Odds ratio and P value comparing BMI up to 35 and 36 or more 











Table 13 shows that a significantly higher proportion of HIV positive women suffered 
mild to moderate morbidity from PPH compared to their HIV negative counterparts 
and more HIV negative women had no morbidity from PPH compared to HIV 
positive women. Morbidity was classified according to the morbidity score described 
in chapter 4 above. 
 
Table 13 












None 80 (29.6%) 340 (37.2%) 17 
(37.8%) 
0.712 




168 (62.2%) 484 (52.9%) 15 
(33.3%) 
1.467 
(1.10 – 1.96) 
0.008 
 
Severe  22 (8.2%) 91 (9.9%) 13 
(28.9%) 
0.803 
(0.47 – 1.32) 
0.411 
*Odds Ratios and P values comparing HIV positive with HIV negative group 
 
 
Table 14 shows a comparison of the occurrence of morbidity from PPH in relation to 
maternal age, parity, BMI, mode of delivery, HIV seropositive status and mean 
haemoglobin level at the time of admission to labour ward or prior to caesarean 
section. To simplify the table, morbidity from PPH was divided into two categories of 











chapter 4 above. There was no difference in HIV status or parity in women with no 
morbidity from PPH compared to those with mild/severe morbidity. 
  
Mean age and mean haemoglobin concentration was significantly lower in women 
who had mild to severe morbidity from PPH compared to those who had no 
morbidity. In addition, there was a significantly lower proportion of women with mild 
or severe morbidity who had a BMI over 35kg/m
2
. Also there was a lower proportion 
of women who had a caesarean section delivery in women with mild/moderate 




























Comparison of morbidity from PPH with respect to age, parity, BMI, mode of 
delivery, HIV seropositive status and mean haemoglobin level on admission to 
delivery. 
 No Morbidity 
(n=437) 






Mean age (yrs) 28.45 27.25  0.001 
Age group (yrs) 
Up to 35 































    Up to 35 
   36 and above 











(0.082 – 0.156) 
 
*0.00001 
























(1.038 – 1.909) 
**0.024 
Mean Hb (g/dl) 11.79 10.22  0.00001 
* Odds ratio and P value comparing BMI up to 35 and 36 or more 











5.6 Impact of CD4 count and anti-retroviral therapy provided on the severity 
and morbidity of HIV positive women with PPH 
Table 15 below shows the influence of the level of CD4 count on the severity of PPH 
in HIV positive women. 240 of the 270 HIV positive women with PPH (88.9%), were 
classified as having mild PPH ie had blood loss of 500 – 1200 ml. The severity of 
PPH was not significantly different in women with CD4 count of up to 250cells/mm
3
 
compared to women with CD4 count of more than 250cells/mm
3
. In addition, table 16 
shows that there was no difference in morbidity from PPH in women with CD4 count 
of up to 250cells/mm
3





The influence of CD4 count on the severity of PPH (n=270). 
                  CD4 count (cells/mm
3) 
  
 Up to 250 
   (n=70) 
More than 250 






Mild  62 (88.6%) 166 (89.2%) 12 
(85.7%) 
0.93 
(0.37 – 2.58) 
0.82 
Moderate to 
very severe  
8 (11.4%) 20 (10.8%) 2 (14.3) % 
Total 70 186 14   
*
Odds Ratio and P value comparing severity of PPH between women with CD4 count up to 250 
cells/mm
3

















The influence of CD4 count on the morbidity from PPH (n=270)     
               CD4 count (cells/mm
3
)   
 Up to 250 
(n=70) 









No morbidity  20 (28.6%)  55 (29.6%) 5 (35.7%) 0.95 (0.49 – 
1.81) 
1.00 
Mild to severe     50 (71.4%)  131 (70.4%) 9 (64.3%) 
Total 70 186 14   
*
Odds Ratio and P value comparing severity of morbidity from PPH between women with CD4 count 
up to 250 cells/mm
3
 and those with CD4 count above 250 cells/mm
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HIV treatment with either Zidovudine (AZT) alone or highly active anti-retroviral 
therapy, HAART, (mostly with Zidovudine, Lamivudine and Nevirapine ) did not 
influence the severity of as well as the morbidity from PPH when compared with 
women who had not been on any form of treatment during their pregnancy. This lack 























The study showed that the incidence of postpartum haemorrhage was significantly 
higher in HIV positive women compared to HIV negative women in the two hospitals 
during the study period; 9.9 % of HIV positive women delivering during the study 
period had PPH compared to 7.5% of HIV negative women. The study had sufficient 
power (98.74%) to show this statistically significant difference in the incidence of 
PPH between HIV positive and HIV negative women (p = 0.001). 
 
The severity of postpartum haemorrhage did not differ between HIV positive and 
negative women. However, mild to moderate morbidity from haemorrhage was 
significantly greater in HIV positive women with PPH compared to HIV negative 
women with PPH. It is important to note that according to the definition of at least 
1800ml of blood loss for severe haemorrhage in this study, only 31 women fell into 
the categories of severe and very severe PPH. This was a small number of women to 
be able to meaningfully compare the severity of and morbidity from PPH between the 
two groups of women. 
 
Demographic characteristics of the women such as mean age, parity, previous 
caesarean delivery, gestational age at delivery and mean haemoglobin level at the time 
of admission to labour ward or prior to caesarean section were similar in the HIV 
positive PPH group and the HIV negative PPH group. 
 
Maternal age over 35 years and BMI over 35 kg/m
2
 are known to be risk factors for 











to be made. Of note was our finding that there was a significantly lower percentage of 
women over 35 years of age in HIV positive women with PPH compared to HIV 
negative women.  
 
Similarly, although obesity is a known risk factor for PPH, a significantly lower 
proportion of HIV positive women with PPH had a BMI of 36 kg/m
2
 or more 
compared to HIV negative women. These findings on age and BMI suggest that the 
association between HIV infection and PPH is not due to an increased proportion of 
women with these risk factors for PPH (age and obesity) in the HIV positive group of 
women with PPH; and points to a possible direct effect of the HIV infection. 
However, without the knowledge of the frequency of these parameters in the whole 
delivery population, it is not possible to make this conclusion. 
 
This study had several limitations. Since it was a retrospective study, some women 
who had PPH may not have been recorded in the labour ward and operating theatre 
registers and therefore may have been left out of the study. In addition, not all the 
required information could be found in the women’s records. Information such as 
booking haemoglobin level, height and weight measurements and haemoglobin level 
at the time of admission to labour ward for delivery was particularly lacking.  
 
Since demographic and other data on women delivering at the two hospitals during 
the study period who did not suffer PPH were not retrieved, the proper assessment of 













The selection of Mowbray Maternity and Groote Schuur Hospitals may have 
presented a biased sample with women who may have been sicker from the HIV 
disease compared to HIV positive women accessing care at the MOU. In addition, the 
aetiology of PPH in these hospitals may have been influenced by the high prevalence 
of conditions such as hypertension and abruptio placentae. As such, the results of this 
study are not generalized to the general population.   
 
Although widely accepted, the clinical visual estimation of blood loss at the time of 
delivery is known to be inaccurate and prone to intra as well as inter-observer error 
with a tendency towards underestimation. A more accurate measure of blood loss 
would be more appropriate for research settings. However, this is not achievable with 
a retrospective study design. 
 
Additionally, since an assessment of other haematological indices such as platelet 
count which may affect the rates of PPH between the two study groups is not 
routinely done in clinical practice, it is not possible to explain why there could be a 
significant difference in the rates of PPH. 
 
The causes of haemorrhage were similar between the two groups of women with 
uterine trauma at caesarean section being the most common cause. This was bleeding 
mainly from the incision site during caesarean section. Such bleeding included that 
from uterine tears extending from the caesarean section incision and intentional 
extensions of the uterine incision due to difficult delivery of the baby among others. 
This finding is in keeping with the findings of the National Committee on 











triennium 2005 – 2007
72
. It is important to note that by having deliveries from 
Mowbray Maternity and Groote Schuur Hospitals alone, the sample may have been 
biased towards more caesarean deliveries due to the high rates of such deliveries in 
these hospitals. A sample including MOUs where normal vaginal deliveries take place 
may have shown a different pattern of PPH causes. 
 
Hypertension was more frequent in the HIV negative PPH group than in the HIV 
positive PPH group. This may be a result of a reduced incidence of pre-eclampsia in 
the HIV positive PPH group due to inhibition of immune hyper-reactivity from the 
immune deficiency state. There are however conflicting findings from studies that 






In this study, 60% of all the women who had post-partum haemorrhage had 
emergency caesarean delivery. This was the most common mode of delivery in all the 
three groups of women (positive, negative and untested). It is well known from 
literature that emergency caesarean section is a risk factor for obstetric 
haemorrhage
74
. The difference in mean blood loss at emergency caesarean section 
between HIV positive and HIV negative women with PPH was almost statistically 
significant (p=0.067). The impact of HIV infection on haemorrhage at emergency 
caesarean section therefore requires further exploration. 
 
It is also interesting to note that a significantly higher proportion of HIV negative  
women with PPH (28.2%) compared to HIV positive women with PPH (21.5%) did 
not require any intervention to arrest bleeding (p=0.028). Uterine trauma at caesarean 











may suggest that these women generally have better functioning clotting mechanisms 
compared to the HIV positive women. 
 
Despite having a similar mean haemoglobin level of 10.8g/dL prior to delivery and a 
non significantly different mean blood loss (p=0.697), more HIV positive women had 
anaemia with haemoglobin level of 10g/dL or less by the second or third day 
following the episode of PPH. The effect of HIV infection on different haematopoietic 




Considering the severity of PPH, in the combined group of women with PPH (ie both 
HIV positive, HIV negative and untested women), the mean haemoglobin at the time 
of admission to labour ward or prior to caesarean delivery was significantly lower in 
women who had blood loss of 1200ml or more compared to those with blood loss less 
than 1200ml. Anaemia in HIV positive women could therefore be an important factor 
predisposing HIV positive women to more severe consequences of PPH. 
 
Considering morbidity from PPH, the mean age and mean haemoglobin at the time of 
admission to labour ward or prior to performing caesarean section was significantly 
lower for women with mild to severe morbidity compared to those with no morbidity. 
Also the proportion of women with increased BMI (over 35kg/m
2
) and the proportion 
of women having a caesarean section delivery was less in women with mild to severe 
morbidity compared to those with no morbidity.  These findings are not in keeping 
with the literature which shows that advanced maternal age and increased BMI are 
known risk factors for PPH. However as indicated before, due to the lack of 











two hospitals during the study period and did not have PPH, it is not possible to 
adequately assess these risk factors for PPH. It is therefore not possible to assess 
whether they could be possible confounding factors for the association between HIV 
positive status and an increased morbidity from PPH. 
 
Out of the 1230 cases of postpartum haemorrhage in this study, only 27 cases of 
hypovolaemic shock following PPH were documented. Twenty-four of these were in 
the HIV negative group, two in the untested group and only one in the HIV positive 
group. It is thought that there was poor documentation of hypovolaemic shock in the 
attending doctor’s notes. There were many women who met the criteria for shock ie 
persistent severe hypotension defined as a systolic blood pressure <90mmHg with a 
pulse rate of at least 120 beats per minute
40
. However, where it was not clearly 
documented that the woman had hypovolaemic shock, the effect of anaesthesia and 
other confounders on these parameters could not be isolated. Therefore, where there 
was no mention that a woman had hypovolaemic shock, no assumption was made that 
they had this complication. 
 
The level of CD4 count at booking for antenatal care, treatment of HIV with either 
Zidovudine alone or highly active anti-retroviral therapy as well as the duration of 
such treatment was not seen to have an impact on the severity of and morbidity from 
PPH. Once again this may be the case because the number of HIV positive women 













The finding of similar results for severity of PPH and morbidity from PPH in the two 
treatment groups of Zidovudine alone and highly active anti-retroviral therapy may 
have been because the majority of patients on HAART were on a Zidovudine 
containing regimen of Zidovudine, Lamivudine and Nevirapine. This was the 
prevailing treatment guideline during the time period under study. 
 
In this study, 3.7% of all the women with PPH were HIV untested. This group 
comprised women who were either unbooked for antenatal care or those that had 
declined HIV testing at booking. As many as 17.8% of these women had abruptio 
placentae as the cause of PPH. These women were not included in the statistical 
analysis for this study. 
 
As shown in the introduction, the Saving Mothers reports for the triennia 2002 – 2004 
and 2005 – 2007 showed that maternal mortality rate from post-partum haemorrhage 
was almost three times higher in HIV positive women compared to HIV negative 
women
2,3
. This could be due to increased incidence of PPH or increased severity of 
PPH in the HIV positive group. 
 
Our study shows an association between HIV infection and an increased incidence of 
PPH. It also showed that the HIV positive PPH group suffered greater morbidity than 
the HIV negative PPH group. However, there was no difference in the severity of 
PPH between the two groups of women. Because of the serious limitations in the 
study design (place of delivery and referral bias, lack of detailed data on women 
without PPH and therefore failure to investigate for confounding), the weak strength 











the absence of the difference in mean blood loss, we cannot conclude that HIV is an 
independent risk factor for PPH.  
 
Further research which is appropriately designed and powered to investigate the 
relationship between HIV disease and its treatment, CD4 count and post-partum 
haemorrhage is required considering the burden of the disease in sub-Saharan Africa 
in general and South Africa in particular where maternal mortality ratio in HIV 
positive women is as high as 327.7 per 100,000 livebirths compared to 34.4 per 




The relationship between the level of CD4 count and the rate of post-partum 
haemorrhage needs to be investigated.  This study did not have a large enough number 
of HIV positive women with PPH to investigate this relationship and data regarding 
the level of CD4 count for the entire HIV positive population of women delivering at 
the two hospitals in 2009 was not collected. Future research should be aimed at 
exploring this relationship.  
 
Another area of future study should be the impact of the different HIV treatment 



















The results of this study demonstrate a significant association between HIV infection 
and an increased incidence of postpartum haemorrhage at Mowbray Maternity and 
Groote Schuur Hospitals. HIV infection was also associated with increased morbidity 
from PPH in the HIV positive PPH group. However, it was not associated with 
increased severity of PPH.  
 
Post-partum haemorrhage is a major cause of maternal mortality especially in low 
resource settings. Unfortunately, it is in these same, often rural areas that the 
prevalence of HIV infection is high. Such areas in sub-Saharan Africa also suffer a 
huge shortage of skilled health care workers and other essential resources such as 
blood products. 
 
Due to the serious study limitations, our study could not establish that HIV infection 
is an independent risk factor for post-partum haemorrhage. More research is required 
to explore the relationship between HIV infection and both the incidence of post-
partum haemorrhage and the morbidity associated with PPH. In order to investigate 
whether HIV infection independently predisposes to PPH, a comprehensive 
exploration of confounding factors would be necessary. If such an association is 
confirmed, there is need to investigate the role of other anti-retroviral treatments in 
increasing severity of and morbidity from PPH. 
 
Given the apparent association between HIV infection and PPH, health care workers 











surgical management of post-partum haemorrhage. Most of the haemorrhage will 
respond to the simple measures without resort to hysterectomy. It is also important 
that people working in lower level health facilities quickly recognise this complication 
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THE EFFECT OF HIV INFECTION ON THE INCIDENCE AND SEVERITY 
SECTION 1: DEMOGRAPHIC DATA
1. Age:______________ 2. Parity:___________ 3. Gravidity:_________
4. Folder Number: _________ 5. Hospital Code:_________ 6. GA at delivery:______ wks
SECTION 2: PAST OBSTETRIC AND GYNAECOLOGICAL HISTORY
7. Previous Deliveries







8. History of PPH Yes [1]       No [2] If no go to Question 11
If yes, state cause:_________________________________________________________
Was transfusion required   Yes [1]    No [2]




9. Previous Miscarriages  Yes [1]    No [2]
Gestational Age ______________ Weeks
Intervention:       Medical [1]    Surgical [2]    Other [3] (Specify):_____________
10. Previous Gynaecological Surgery  Yes [1]    No [2]
If Yes, name operation:___________________________________________
Other abdominal surgery  Yes [1]    No [2]
If yes, specify:____________________________________________________
SECTION 3: INDEX PREGNANCY











11. Booked  Yes [1]    No [2]
12. Gestational age at booking __________ weeks
13. Date of booking   __________
14. Weight at booking: ____________ Kg
15. Height: _______________ Metres          
16. BMI: ___________ Kg/sqm
17. Booking Hb:______ g/dL
18. Hb on Admission:___________ g/dL 19. APH  Yes [1]    No [2]
20. Blood Group: A [1]  B [2]  AB [3]  O [4]
21. RPR:       Postive [1]    Negative [2] 22. Rhesus:    Postive [1]    Negative [2]
23. HIV          Postive [1]    Negative [2]
24. CD4 count:________________ 25. Date Taken ______________
26. Treatment:  Zidovudine [1]  Heamatinics [2]  HAART [3]
   HAART state regime:__________________ Date commenced:_________
27. Duration of treatment:_____________ wks 
28. Ultrasound Done  Yes [1]    No [2]
29. Gestation at 1st ultrasound: _______Weeks
30. Concurrent medical disorders: Hypertension Hypertension  Yes [1]    No [2]
Diabetes Mellitus  Yes [1]    No [2]
Thyroid  Yes [1]    No [2]
Bleeding disorder  Yes [1]    No [2]
Gestational hpt  Yes [1]    No [2]
Abruptio placenta  Yes [1]    No [2]
Other (specify):________________________________
31. Nature of gestation Single [1]  Multiple [2]
If multiple, state order:_______________________________________
32.Mode of Delivery Elective CS [1]  Emergency CS [2]  NVD [3]  Breech [4]
Forceps [5]  Ventouse [6]
33. Indication for CS: ______________________________________
34. Anaesthetic Spinal [1]  General [2]










36. Place of Delivery Home [1]  MOU [2]  Level 2 [3]  Level 3 [4]  
Enroute to health Facility [5] 
Other [6] (Specify):_____________________________
SECTION 4: DETAILS OF PPH
37. Estimated blood loss: ____________ ml
38. Lowest Hb recorded after PPH: _________ g/dL
39. Lowest BP at time of diagnosis: __________ mmHg
40. Pulse rate at time of diagnosis:________________
41. Cause of PPH: Uterine atony [1]  Retained Placenta [2]  
Retained products of conception [3]  Trauma Vag [4]
                      Trauma Cer  [5] Trauma Ut [6] Uterine rupture [7]
Post Abr. Placenta [8]  Post Placenta Pre. [9] 
Anticoagulation treatment [10] 
42. Intervention Oxytocin [1]    Ergometrine [2]    Misopostol [3] F2 Alpha [4]  MROP [5]  Evac [6]  
Repair of Tear [7]  B-Lynch suture [8]  Balloon Tamponade [9] Hysterectomy [10]  
Abdominal Packing [11]  Suture [11]
43. Blood products given    Yes [1]    No [2]
Packed cells:  ________ units
Fresh frozen plasma: ________ units
Cryoprecipitate:  ________ units
Other (specify):_________________________________________
44. Severity score: normal blood loss [0]  Mild [1]  moderate [2]  severe [3]  very severe [4]
45. Morbidity score:  none [0]  mild [1]  moderate [2]  severe  [3]  very severe [4]
SECTION 5: COMPLICATIONS OF PPH
46. Hypovolaemic shock Yes [1]     No [2]
47. Disseminated intravascular coagulation Yes [1]     No [2]
48. Acute renal failure Yes [1]     No [2]
49. Hepatic failure Yes [1]     No [2]
50. Adult respiratory distress syndrome Yes [1]     No [2]
51. Other (specify) 










52. Transfusion reactions    Yes [1]    No [2]
53. Fluid Overload  Yes [1]    No [2]
54. Need for assisted ventilation  Yes [1]    No [2]
55. Infection  Yes [1]    No [2]
             If yes, state site:_________________________________
56. Uterine perforation  Yes [1]    No [2]
57. Bladder injury  Yes [1]    No [2]
58. Ureteric injury  Yes [1]    No [2]
59. Bowel inury  Yes [1]    No [2]
SECTION 7: FINAL OUTCOME
60. Outcome of baby: Alive [1]   Stillbirth [2]




61. Alive and well at discharge  Yes [1]    No [2]
62. Disability  Yes [1]    No [2]
      If yes, give details:____________________________________________
63. Death  Yes [1]    No [2]
   
64. Duration of hospital stay                                                Days
65. Admission to MK SCU             Yes [1]    No [2]
    If yes, give duration of stay                                                 Days
66. Admission to other ICU             Yes [1]    No [2]
    If yes, specify location
    Duration of Stay                                                                Days
